MedTrace Logo

TREXIMA and RELPAX Gastric Scintigraphy Inside and Outside a Migraine

NCT00385008 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2018-02-12

Study results available
· View outcomes & findings →

Summary

An evaluation of tablet disintegration and absorption and gastric transit of sumatriptan and naproxen sodium from a TREXIMA tablet and eletriptan from a RELPAX 40mg tablet.

Conditions

  • Migraine Disorders

Interventions

DRUG

Combination Product (sumatriptan succinate / naproxen sodium)

sumatriptan/naproxen sodium

DRUG

RELPAX(eletriptan) 40mg Tablet

eletriptan tablets

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-09-13
Primary Completion
2006-11-24
Completion
2006-11-24

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00385008 on ClinicalTrials.gov